Senza Omnia is a spinal cord stimulation system designed to deliver Nevro’s HF10 therapy and all SCS frequencies between 2Hz and 10,000Hz. Credit: Nevro Corp.

Medical device company Nevro has launched Senza Omnia Spinal Cord Stimulation (SCS) System to treat chronic pain in the US, following the US Food and Drug Administration (FDA) approval.

The system delivers SCS frequencies between 2Hz and 10,000Hz, along with the company’s HF10 therapy, which combines a 10kHz frequency and a treatment algorithm.

Related Company Profiles

View all

HF10 is a non-pharmacologic neuromodulation platform to treat chronic pain.

Senza Omnia consists of a programmer to allow physicians to provide a variety of waveforms, separately or in combination, across the SCS frequency spectrum.

The device comes with a patient remote to support extended programming capacity. It enables expansion on the HF10 algorithm, where physicians can offer additional waveforms.

Nevro integrated Senza Omnia with an upgradeable implantable pulse generator, which can last for more than ten years, irrespective of the stimulation profile.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company added that the system has conditional full-body MRI approval, with the potential to upgrade to future waveforms and frequencies.

Nevro chairman and CEO Keith Grossman said: “The Omnia system was developed based on feedback from the pain community and has resulted in a product that Nevro is uniquely able to provide.

“Omnia not only offers HF10, the most studied therapy available in the market that physicians have provided to over 53,000 patients but it also gives physicians access to all other SCS frequencies, either independently or paired with HF10.”

The company expects to secure regulatory approvals in Europe, as well as Australia next year.

Nevro initially developed the Senza SCS system for non-pharmacologic treatment of chronic pain. Its portfolio currently includes the Senza System, Senza II System and Senza Omnia System.